The REVELIO Study, a project out of CDHI’s Core for Digital Biomarkers in Driver Health and Safety, is recruiting participants.

Background of the study: People who regularly consume cannabis have elevated blood concentrations of THC for days after the consumation.  Due to a zero tolerance regulation, they therefore risk the loss of their driver’s license, even though there is no indication of reduced capacity for safe driving once the initial effects of cannabis consumption have receded.  The REVELIO Study aims to develop a driver assistance system which can predict the actual ability of a driver to safely operate a vehicle, independently of the THC values present in blood. This has the potential to reduce traffic accidents while also avoiding regular cannabis consumers from being categorically classified as unfit to drive.

Participants will perform various driving tasks on a closed test track both under the influence of cannabis (after smoking a joint consisting of a 1:1 mixture of tobacco and cannabis with 18% THC / < 1% CBD) and without.

For questions or inquiries, please contact Christoph Karl Heck .

Please share widely with your networks!